期刊文献+

3-氨基苯甲酰胺衍生物PARP-1抑制剂的设计合成及活性评价

Synthesis and biological evaluation of PARP-1 inhibitors with 3-aminobenzamide skeleton
原文传递
导出
摘要 目的设计合成新型结构的聚腺苷二磷酸核糖聚合酶(PARP-1)抑制剂并评价其对PARP-1的抑制活性。方法基于已有构效关系和药效团特征设计了一系列3-氨基苯甲酰胺类化合物;以3-氨基苯甲酰胺或2-氟-5-氨基苯甲酰胺为起始原料与N-Boc保护的含氮脂环羧酸反应,经缩合、脱除Boc保护基、还原胺化反应合成目标化合物。利用NAD^+化学定量法评价目标化合物对PARP-1的抑制活性。结果合成了30个未见文献报道的3-氨基苯甲酰胺类衍生物,目标化合物的结构经~1H-NMR、LC-MS谱确证,其中20个化合物对PARP-1具有一定的抑制活性(IC_(50)值为0.19~7.58μmol·L^(-1))。结论初步探讨了该类化合物的构效关系,利用分子对接方法探索了目标化合物与PARP-1的作用模式,以期为进一步结构改造提供参考。 PARP-1[poly(ADP-ribose) polymerase-1]is involved in a DNA repair process by catalyzing the transfer of ADP-ribose units from NAD to a number of its substrate proteins.It is a promising anticancer drug target and many PARP-1 inhibitors have been developed and used in the clinical trial.In this work,a series of novel 3-aminobenzamide derivatives was designed and synthesized and their inhibitory activities against PARP-1 were evaluated.Of all the tested compounds,twenty compounds displayed inhibitory activities with IC_(50) values ranging from 0.19 to 7.58 μmol·L^-1.The binding pose of compound 4c(R= F,R^1= H,R^2= isobutyl) was predicted using molecular docking to facilitate further structural modification.
出处 《中国药物化学杂志》 CAS CSCD 2016年第3期165-174,181,共11页 Chinese Journal of Medicinal Chemistry
基金 中央级公益性科研院所基本科研业务费资助项目(2013CHX16)
关键词 聚腺苷二磷酸核糖聚合酶(PARP-1) 抑制剂 3-氨基苯甲酰胺 抗肿瘤药物 PARP-1 inhibitor 3-aminobenzamide antitumor drug
  • 相关文献

参考文献5

二级参考文献44

  • 1Lindsay GBALL,Wei XIAO.Molecular basis of ataxia telangiectasia and related diseases[J].Acta Pharmacologica Sinica,2005,26(8):897-907. 被引量:4
  • 2张文婷,鄢浩,姜凤超.聚腺苷二磷酸核糖聚合酶-1抑制剂药效团模型的建立[J].药学学报,2007,42(3):279-285. 被引量:3
  • 3Zhenping ZHU.Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor:status and perspectives[J].Acta Pharmacologica Sinica,2007,28(9):1476-1493. 被引量:10
  • 4Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays, 2004, 26: 882-893.
  • 5Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev, 2002, 54: 375-429.
  • 6Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem, 2010, 53: 4561-4584.
  • 7Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair, 2004, 3: 1103-1108.
  • 8Lupo B, Trusolino L. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. BBA-Rev Cancer, 2014, 1846: 201-215.
  • 9Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R, Rodríguez MI, Linares JL, de Almodóvar MR, Oliver FJ. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radical Bio Med, 2009, 47: 13-26.
  • 10Langelier MF, Planck JL, Roy S, Pascal JM. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science, 2012, 336: 728-732.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部